Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2306MR)

This product GTTS-WQ2306MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2306MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5454MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ10530MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ2373MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ12533MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ5769MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ8076MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ13069MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ1743MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW